

OKLAHOMA BOARD OF NURSING  
2915 North Classen Boulevard, Suite 524  
Oklahoma City, OK 73106  
(405) 962-1800

**Formulary Advisory Council**  
**July 31, 2017**

**2:30 p.m.**

**Basement Conference Room, Cameron Building**

**AGENDA**

1. Call to order
  - 1.1 Declaration of a quorum
2. Decision regarding approval of August 16, 2016, meeting minutes (**Attachment #1**)
3. Board Updates: Verbal reports
  - 3.1 Changes to the *Oklahoma Nursing Practice Act*-Jackye Ward
  - 3.2 Changes to the Rules of the Oklahoma Board of Nursing-Jackye Ward
  - 3.3 New Enhanced Nurse Licensure Compact-Jackye Ward
  - 3.4 Formulary Advisory Council members-expiration of appointments
  - 3.5 Advanced Practice Advisory Committee Bylaws changes-Jackye Ward
  - 3.6 Update regarding the Comprehensive Action Recovery Act-Gina Stafford
  - 3.7 Other (verbal report only, no discussion)
4. Review and decision on *Request to Amend the Formulary* received March 3, 2017 and sent by Verna Foust on behalf of The Oklahoma Behavioral Health Association, requesting to no longer exclude the prescribing of Opiate Partial Agonists for the management of narcotic dependency. Nine letters of support were included with the request.
  - *Request to Amend* (**Attachment # 2**)
  - Letter-Oklahoma Behavioral Health Association (**Attachment #2A**)
  - Letter-Debbi McCulloch, DNP, MS (**Attachment #2B**)
  - Letter-Grand Lake Mental Health Center (**Attachment #2C**)
  - Letter-Susan Jacob, APRN (**Attachment #2D**)
  - Letter-Creoks Behavioral Health Services (this letter was include with this request and sent separately February 21, 2017) (**Attachment #2E**)
  - Letter-Robin Potter-Kimball, APRN (**Attachment #2F**)
  - Letter-Olesia Grellner, APRN (**Attachment #2G**)
  - Letter-Ragina Holiman-James, APRN (**Attachment #2H**)
  - Letter-Scott Scammahorn, APRN-CNP (**Attachment #2I**)
  - *What exactly is Buprenorphine?* (**Attachment #2J**)
  - National Institute on Drug Abuse, presented by Nora D. Volkow, M.D (**Attachment #2K**)

- State of Addiction: Oklahoma ranked No. 1 state in prescription painkiller abuse (**Attachment #2L**)
  - Tulsa News (**Attachment #2M**)
  - American Society of Addiction Medicine, *Congress Passes CARA!* (**Attachment #2N**)
  - Suboxone Highlights of Prescribing Information (**Attachment #2O**)
5. Review and decision on the recommendation to remove Clozapine from the Exclusionary Formulary
    - *Clozapine and the Risk of Neutropenia: A Guide for Healthcare Providers* (**Attachment #3**)
    - Clozapine REMS-*New Safety Information Required by FDA* (**Attachment #3A**)
    - Prescriber Designee Enrollment Form (**Attachment #3B**)
    - ANC Lab Reporting Form, (**Attachment #3C**)
    - History regarding Exclusionary Formulary and Clozapine (**Attachment #3D**)
    - Survey response from Mental Health APRNs regarding Clozapine
  6. Review and recommendations to the Oklahoma Board of Nursing on revisions to the Exclusionary Formulary for Advanced Practice Registered Nurses with Prescriptive Authority, #P-50B
    - DRAFT (**Attachment #4**)
    - AHFS 2016 Drug Assignment and Reassignments- All circled dates occurred after our last meeting (**Attachment #4A**)
    - AHFS 2017 Drug Assignments and Reassignments (**Attachment #4B**)
    - Section 303 of the Comprehensive Addiction Recovery Act (**Attachment #4C**)
    - FDA information on Noctiva- (**Attachment #4D**)
  7. Review and recommendations to the Oklahoma Board of Nursing on the Formulary Advisory Council Procedure for Amending the Formulary, #P-50 (**Attachment #5**)
  8. Council decision regarding election of chairperson and vice-chairperson
    - 8.1 Chairperson
    - 8.2 Vice-Chairperson
  9. Date for next meeting
  10. Adjournment